Azathioprine
Administration
- Type: immunosuppressant
- Dosage Forms: tablet, powder for injection (IV form unavailable in US)
- Dosage Strengths: tablet: 50, 75, 100mg; powder for injection: 100mg/vial
- Routes of Administration: PO, IV (unavailable in US)
- Common Trade Names: Azasan, Imuran
Adult Dosing
Kidney transplant rejection prophylaxis
- 1-3mg/kg PO QD
- Start: 3-5mg/kg PO x1 up to 3 days before transplant; Info: transplant protocols may vary
Rheumatoid arthritis, severe
- 1-2.5mg/kg/day PO divided QD-bid
- Start: 1mg/kg/day PO divided QD-bid; Max: 2.5mg/kg/day; Info: after 6-8wk may increase 0.5mg/kg/day q4wk
Crohns Disease
- 100-250mg PO QD
- Start: 50mg PO QD; Max: 2.5mg/kg/day; Info: for induction or remission maintenance and fistulizing disease, steroid-sparing effects
Ulcerative colitis
- 100-250mg PO QD
- Start: 50mg PO QD; Max: 2.5mg/kg/day; Info: for induction or remission maintenance, steroid-sparing effects
Pediatric Dosing
Kidney transplant rejection prophylaxis
- 1-3mg/kg PO QD
- Start: 3-5mg/kg PO x1 up to 3 days before transplant; Info: transplant protocols may vary
Juvenile idiopathic arthritis, severe
- 1-2.5mg/kg/day PO divided QD-bid
- Start: 1mg/kg/day PO divided QD-bid; Max: 2.5mg/kg/day; Info: after 6-8wk may increase 0.5mg/kg/day q4wk
Special Populations
- Pregnancy Rating: Pregnancy Category D
- Lactation risk: possibly unsafe
Renal Dosing
- Adult: CrCl 10-50: decrease dose 25%; CrCl <10: decrease dose 50%; HD: give 0.25mg/kg supplement; PD: not defined
- Pediatric: CrCl 10-50: decrease dose 25% or give q36h; CrCl <10: decrease dose 50% or give q48h; HD: give supplement; PD: not defined
Hepatic Dosing
- Adult: not defined; caution advised
- Pediatric: not defined; caution advised
Contraindications
- Allergy to class/drug
- pregnancy (RA use)
- caution if renal impairment
- caution if prior alkylating agents
Adverse Reactions
Serious
- leukopenia
- thrombocytopenia
- anemia
- myelosuppression
- immunosuppression
- infection
- PML
- GI hypersensitivity reaction
- pancreatitis
- hepatotoxicity
- hepatic veno-occlusive disease
- lymphoma
- malignancy
- acute febrile neutrophilic dermatosis
Common
- leukopenia
- thrombocytopenia
- anemia
- infection
- nausea
- vomiting
- anorexia
- diarrhea
- ALT, AST elevated
- malaise
- myalgia
- fever
- rash
- malignancy
Pharmacology
- Half-life: 5 hours
- Metabolism: liver extensively, erythrocytes; CYP450
- Excretion: bile, urine (1-2% unchanged)
Mechanism of Action
Acts as a prodrug for mercaptopurine, inhibiting an enzyme required for the synthesis of DNA. Thus, it most strongly affects proliferating cells, such as the T cells and B cells of the immune system
Comments
See Also
References
- A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group. J Neurol Neurosurg Psychiatry. 1993;56(11):1157-1163. [PubMed 8229026]
- American College of Rheumatology Ad Hoc Committee on Clinical Guidelines, “Guidelines for Monitoring Drug Therapy in Rheumatoid Arthritis,” Arthritis Rheum, 1996, 39(5):723-31. [PubMed 8639168]
- Astey AV, Wakelin S, and Reynolds NJ, “Guidelines for Prescribing Azathioprine in Dermatology,” Br J Dermatol, 2004, 151(6):1123-32. [PubMed 15606506]
- Armuzzi A, Felice C, Papa A, et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study. J Crohns Colitis. 2013;7(12):e623-e629. doi: 10.1016/j.crohns.2013.04.020. [PubMed 23810678]
- Arnold DM, Nazi I, Santos A, et al, “Combination Immunosuppressant Therapy for Patients With Chronic Refractory Immune Thrombocytopenic Purpura,” Blood, 2010, 115(1):29-31. [PubMed 19897578]
- Aronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97, 177.
- Azasan (azathioprine) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; March 2019.
- Azathioprine injection [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; August 2015.
- Baum D, Bernstein D, Starnes VA, et al, “Pediatric Heart Transplantation at Stanford: Results of a 15-Year Experience,” Pediatrics, 1991, 88(2):203-14. [PubMed 1861916]
- Beissert S, Werfel T, Frieling U, et al, "A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Pemphigus," Arch Dermatol, 2006, 142(11):1447-54. [PubMed 17116835]
epocrates